How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,979 results for

Long-Acting Reversible Contraception

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Long-term hormonal contraceptive use is associated with a reversible suppression of antral follicle count and a break from hormonal contraception may improve oocyte yield (PubMed)

Long-term hormonal contraceptive use is associated with a reversible suppression of antral follicle count and a break from hormonal contraception may improve oocyte yield Unlike infertility, patients presenting for fertility preservation (FP) are often using combined hormonal contraceptives (CHC). We studied whether long-term (≥6 months) CHC use is associated with reversible suppression of antral follicle count (AFC).This is a longitudinal study of FP cycles from 2012 to 2016. We studied three (...) groups: those without CHC exposure (NO CHC), those with CHC usage with a CHC break (BREAK), and without a break (NO BREAK) prior to ovarian stimulation. We assessed ovarian reserve by AFC at initial consultation and discussed the possibility of CHC suppression of AFC. Patients chose between ovarian stimulation with no CHC break versus ovarian stimulation after a CHC break. AFC was measured serially in the BREAK group. We assessed whether AFC suppression was reversed in the BREAK group. Total oocyte

Full Text available with Trip Pro

2017 Journal of assisted reproduction and genetics

142. Assessment of Cultural Acceptability of Long Acting Contraception in a Diverse, Urban Population

topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Intervention arm Participants in the intervention arm will be asked to watch a short educational video on LARC (Long acting reversible contraceptive) and to complete a survey before and after watching the video. Behavioral: Educational video on LARC Participants will watch a short educational video on long acting reversible contraceptive or LARC No Intervention: Control arm Participants in the intervention arm will only (...) Assessment of Cultural Acceptability of Long Acting Contraception in a Diverse, Urban Population Assessment of Cultural Acceptability of Long Acting Contraception in a Diverse, Urban Population - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2018 Clinical Trials

143. Policy Barriers to Best Practices: The Impact of Restrictive State Regulations on Access to Long-Acting Reversible Contraceptives

Policy Barriers to Best Practices: The Impact of Restrictive State Regulations on Access to Long-Acting Reversible Contraceptives Policy Barriers to Best Practices: The Impact of Restrictive State Regulations on Access to Long-Acting Reversible Contraceptives | RAND Objective Analysis. Effective Solutions. Site-wide navigation Trending Topics Featured Research Activities Spotlight Commentary: Commentary: By Research Area Drawing upon decades of experience, RAND provides research services (...) School Assistant Policy Researcher, RAND; Ph.D. Candidate, Pardee RAND Graduate School Site-wide Search Search Scientific evidence supports long-acting reversible contraceptive (LARC) methods for first-line use as birth control. Studies have shown that LARC methods, which include the intrauterine device (IUD) and subdermal implant, are highly effective, very safe, preferable to women, and cost effective. Despite these data, low rates of LARC use persist in the United States; LARCs were selected

2015 The RAND blog

144. Condom use in adolescents and young women following initiation of long- or short-acting contraceptive methods. (PubMed)

Condom use in adolescents and young women following initiation of long- or short-acting contraceptive methods. The objective was to determine if young women initiating long-acting reversible contraceptives (LARCs) who report new sexual partner(s) would be less likely to report use of a condom than women using short-acting reversible contraceptive (SARC) methods.We enrolled a prospective cohort of 13-24-year-old women attending an adolescent-specific contraception clinic. Participants completed (...) questionnaires at the contraceptive initiation visit and 6 months later. At follow-up, we asked if they had sexual intercourse with a new partner, if they had used condoms, if their condom use patterns had changed and why. We analyzed factors associated with condom use.We enrolled 1048 women; 771 (73.6%) initiated LARC and 384 (36.6%) initiated SARC. At 6 months, 508 participants (48.5%) completed the follow-up survey: 380 LARC initiators and 128 SARC initiators. Approximately 23% of LARC initiators and 27

2017 Contraception

145. Clinical effectiveness of Etonorgestrel Contraceptive Implant (Nexplanon/Implanon-NXT) as compared to other Long Acting Reversible Contraceptive (LARC) methods and female sterilization in women of reproductive age group

Clinical effectiveness of Etonorgestrel Contraceptive Implant (Nexplanon/Implanon-NXT) as compared to other Long Acting Reversible Contraceptive (LARC) methods and female sterilization in women of reproductive age group Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any

2018 PROSPERO

146. Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception

Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02446821 Recruitment Status : Active, not recruiting First Posted : May 18, 2015

2015 Clinical Trials

147. Views of general practitioners on providing contraceptive advice and long-acting reversible contraception at the 6-week postnatal visit: a qualitative study. (PubMed)

Views of general practitioners on providing contraceptive advice and long-acting reversible contraception at the 6-week postnatal visit: a qualitative study. Increased uptake of long-acting reversible contraception (LARC) postpartum could prevent more unintended pregnancies and short inter-birth intervals. General practitioners (GPs) play a pivotal role in providing postpartum contraception at the 6-week postnatal visit.To explore how GPs view their role in delivering postpartum contraception (...) at the 6-week visit and on providing LARC at this time.In-depth, semi-structured interviews with a purposive sample of 13 GPs in Edinburgh and the surrounding region in Scotland. The interviews were audio recorded, transcribed and thematically analysed.All GPs confirmed that contraception was routinely discussed at the postpartum visit, although this was usually the last item covered. Most felt that while 6-weeks postpartum was adequate for most women to commence contraception, it was often too late

Full Text available with Trip Pro

2015 Journal of Family Planning and Reproductive Health Care

148. The cost-effectiveness of a long-acting reversible contraceptive (Implanon) relative to oral contraception in a community setting

The cost-effectiveness of a long-acting reversible contraceptive (Implanon) relative to oral contraception in a community setting The cost-effectiveness of a long-acting reversible contraceptive (Implanon) relative to oral contraception in a community setting The cost-effectiveness of a long-acting reversible contraceptive (Implanon) relative to oral contraception in a community setting Lipetz C, Phillips C J, Fleming C F Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of long-acting reversible contraception (LARC, namely Implanon) in comparison with oral contraception in women aged 13 to 48 years. The authors concluded that LARC was a cost-effective alternative to oral contraception

2009 NHS Economic Evaluation Database.

149. Rationale and enrollment results for a partially randomized patient preference trial to compare continuation rates of short-acting and long-acting reversible contraception. (PubMed)

Rationale and enrollment results for a partially randomized patient preference trial to compare continuation rates of short-acting and long-acting reversible contraception. Most published contraceptive continuation rates have scientific limitations and cannot be compared; this is particularly true for dissimilar contraceptives. This study uses a new approach to determine if high continuation rates of long-acting reversible contraception (LARC) and protection from unintended pregnancy (...) are observable in a population not self-selecting to use LARC.We are conducting a partially randomized patient preference trial (PRPPT) to compare continuation rates of short-acting reversible contraception (SARC) and LARC. Only women seeking SARC were invited to participate. Participants chose to be in the preference cohort (self-selected method use) or opted to be randomized to SARC or LARC; only those in the randomized cohort received free product. We compared participant characteristics, reasons

2015 Contraception Controlled trial quality: uncertain

150. Rationale and enrollment results for a partially randomized patient preference trial to compare continuation rates of short-acting and long-acting reversible contraception. (PubMed)

Rationale and enrollment results for a partially randomized patient preference trial to compare continuation rates of short-acting and long-acting reversible contraception. Most published contraceptive continuation rates have scientific limitations and cannot be compared; this is particularly true for dissimilar contraceptives. This study uses a new approach to determine if high continuation rates of long-acting reversible contraception (LARC) and protection from unintended pregnancy (...) are observable in a population not self-selecting to use LARC.We are conducting a partially randomized patient preference trial (PRPPT) to compare continuation rates of short-acting reversible contraception (SARC) and LARC. Only women seeking SARC were invited to participate. Participants chose to be in the preference cohort (self-selected method use) or opted to be randomized to SARC or LARC; only those in the randomized cohort received free product. We compared participant characteristics, reasons

Full Text available with Trip Pro

2015 Contraception Controlled trial quality: uncertain

151. Cohort study: Oral contraceptives do not appear to present long-term cancer harms and may even provide protection against some cancers

prescribe combined oral contraceptive (COCs) and counsel patients about COCs are in a position to ensure balanced discussion as they improve patient knowledge of known benefits and risks. Prescribers presenting health teaching should have an equal focus on the benefits and risks. Future research should include side-by-side comparisons of COCs and other types of fertility control (ie, long-acting reversible contraceptives and/or vaginal rings) to provide women with the evidence needed to make informed (...) Cohort study: Oral contraceptives do not appear to present long-term cancer harms and may even provide protection against some cancers Oral contraceptives do not appear to present long-term cancer harms and may even provide protection against some cancers | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log

2018 Evidence-Based Nursing

152. Lessons from the Contraceptive CHOICE Project: the Hull long-acting reversible contraception (LARC) initiative. (PubMed)

Lessons from the Contraceptive CHOICE Project: the Hull long-acting reversible contraception (LARC) initiative. To discover whether a hand-out explaining the benefits of intrauterine contraceptives (IUCs) and implants could increase their uptake in Hull, UK.We developed a simple double-sided A4 hand-out. On one side was a script with pictures of copper and levonorgestrel IUCs next to a 20 pence coin and of an implant beside a hairgrip. On the other side was the three-tiered effectiveness chart (...) to stop dispensing hand-outs.This was not a formal study, so there was no research coordinator to monitor the project. We think that there was no impact among GPs because the project was not implemented by them. The project was poorly implemented at the four satellite FP clinics. Only the service hub implemented the project, where it had a clear impact. We conclude that when implemented as intended, this simple, very low-cost long-acting reversible contraception intervention was highly effective

Full Text available with Trip Pro

2014 Journal of Family Planning and Reproductive Health Care

153. Midwives' experiences and views of giving postpartum contraceptive advice and providing long-acting reversible contraception: a qualitative study. (PubMed)

Midwives' experiences and views of giving postpartum contraceptive advice and providing long-acting reversible contraception: a qualitative study. National sexual health frameworks in the UK advise that women in maternity units who are at risk of unintended pregnancy should receive contraceptive advice and supplies of the most effective long-acting reversible methods of contraception (LARC). In the UK, midwives currently deliver contraceptive advice to women following childbirth (...) . There is a lack of information on how midwives currently view their role as provider of contraceptive advice and how they would feel about expanding this to include provision of LARC.To explore midwives' experiences and views of giving postpartum contraceptive advice and of possible expansion of role to include provision of LARC.Semi-structured, audio-recorded interviews were carried out with 12 midwives involved in the postpartum care of women in Edinburgh, Scotland, UK. Interviews were transcribed verbatim

Full Text available with Trip Pro

2014 Journal of Family Planning and Reproductive Health Care

154. Obstetrician-Gynecologists and contraception: long-acting reversible contraception practices and education. (PubMed)

Obstetrician-Gynecologists and contraception: long-acting reversible contraception practices and education. Long-acting reversible contraception (LARC) - the copper and levonorgestrel intrauterine devices (IUDs) and the single-rod implant - are safe and effective but account for a small proportion of contraceptive use by US women. This study examined obstetrician-gynecologists' knowledge, training, practice and beliefs regarding LARC methods.A survey questionnaire was mailed to 3000 Fellows (...) be reduced if more obstetrician-gynecologists received implant training and provided same-day IUD insertion. Continuing education will likely increase implant provision.This study shows that obstetrician-gynecologists generally offer IUDs, but fewer offer the single-rod contraceptive implant. Recent continuing education strongly predicted whether obstetrician-gynecologists inserted implants and was also associated with other practices that encourage LARC use.Copyright © 2014 Elsevier Inc. All rights

2014 Contraception

155. 'But you can't reverse a hysterectomy!' Perceptions of long acting reversible contraception (LARC) among young women aged 16-24 years: a qualitative study. (PubMed)

'But you can't reverse a hysterectomy!' Perceptions of long acting reversible contraception (LARC) among young women aged 16-24 years: a qualitative study. Long Acting Reversible Contraception (LARC) methods are highly effective in reducing the incidence of unwanted pregnancy. Recent data indicates that the rate of abortion in Grampian, North East of Scotland is above the Scottish average and LARC uptake among young women low. This study sought to explore young women's perceptions of LARC (...) interviewed were aware of some of the delivery systems used for long acting contraception (intrauterine devices, implants and injections) but did not recognise them as 'LARC'. 'Long acting' was equated with permanency and the term 'reversible' appeared to have the opposite effect to its intention. Intrauterine devices were commonly referred to as 'coil'. The women often relied on verbal testimonies from those who had experienced using LARC, many of which were negative and inaccurate. A lack of in-depth

2014 Public health Controlled trial quality: uncertain

156. Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)- Positive Subjec

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)- Positive Subjec Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV (...) )- Positive Subjects From the LATTE Study - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA

2018 Clinical Trials

157. Improving Access to Long-Acting Contraceptive Methods and Reducing Unplanned Pregnancy Among Women with Substance Use Disorders (PubMed)

Improving Access to Long-Acting Contraceptive Methods and Reducing Unplanned Pregnancy Among Women with Substance Use Disorders Much has been written about the consequences of substance use in pregnancy, but there has been far less focus on the prevention of unintended pregnancies in women with substance use disorders (SUDs). We examine the literature on pregnancy incidence for women with SUDs, the clinical and economic benefits of increasing access to long-acting reversible contraceptive (LARC (...) ) methods in this population, and the current hurdles to increased access and uptake. High rates of unintended pregnancies and poor physical and psychosocial outcomes among women with SUDs underscore the need for increased access to, and uptake of, LARC methods among these women. A small number of studies that focused on improving access to contraception, especially LARC, via integrated contraception services predominantly provided in drug treatment programs were identified. However, a number

Full Text available with Trip Pro

2016 Substance Abuse: Research and Treatment

158. What are the views of health care professionals on long acting reversible contraception (LARC)? A systematic review of qualitative data

What are the views of health care professionals on long acting reversible contraception (LARC)? A systematic review of qualitative data Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

159. Long-acting reversible contraception and STI/HIV prevention implications: a systematic review and meta-analysis

Long-acting reversible contraception and STI/HIV prevention implications: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

160. Efficacy and Safety of Long-Acting Reversible Contraception in Women With Cardiovascular Conditions. (PubMed)

Efficacy and Safety of Long-Acting Reversible Contraception in Women With Cardiovascular Conditions. The physiological changes that occur during pregnancy can be deleterious to women with a cardiovascular condition. Evidence-based contraceptive counseling and provision is essential in this patient population. Although long-acting reversible contraception (LARCs), which include the intrauterine device (IUD) and the etonogestrel contraceptive implant, have been found to be safe and effective (...) in healthy women, there are inadequate data regarding LARC use in patients with cardiovascular conditions. We conducted a retrospective chart review of women diagnosed with cardiovascular disease who had a copper IUD, levonorgestrel-releasing intrauterine system or contraceptive implant placed at the University of Washington Medical Center from 2007 to 2012. We abstracted and analyzed patient demographic characteristics, medical conditions, indications for LARC placement, and complications. The sample

Full Text available with Trip Pro

2015 American Journal of Cardiology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>